These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32540381)

  • 1. Development of a novel truncated deguelin derivative possessing nitric oxide donor as a potential anti-lung cancer agent.
    Zhou H; Dong Y; Ma X; Xu J; Xu S
    Fitoterapia; 2020 Oct; 146():104670. PubMed ID: 32540381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
    Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
    Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
    Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.
    Chun KH; Kosmeder JW; Sun S; Pezzuto JM; Lotan R; Hong WK; Lee HY
    J Natl Cancer Inst; 2003 Feb; 95(4):291-302. PubMed ID: 12591985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro.
    Kang W; Zheng X; Wang P; Guo S
    Int J Mol Med; 2018 Jun; 41(6):3157-3166. PubMed ID: 29512685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
    Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
    Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
    Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
    Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy.
    Kim WY; Chang DJ; Hennessy B; Kang HJ; Yoo J; Han SH; Kim YS; Park HJ; Seo SY; Mills G; Kim KW; Hong WK; Suh YG; Lee HY
    Cancer Prev Res (Phila); 2008 Dec; 1(7):577-87. PubMed ID: 19139008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
    Chen Z; Huang KY; Ling Y; Goto M; Duan HQ; Tong XH; Liu YL; Cheng YY; Morris-Natschke SL; Yang PC; Yang SL; Lee KH
    J Nat Prod; 2019 Nov; 82(11):3065-3073. PubMed ID: 31718182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide donor hybrid compounds as promising anticancer agents.
    Ding QG; Zang J; Gao S; Gao Q; Duan W; Li X; Xu W; Zhang Y
    Drug Discov Ther; 2017 Jan; 10(6):276-284. PubMed ID: 27990006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
    Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
    J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of deguelin on H460 human lung cancer cells in vitro and in vivo: Roles of apoptotic cell death and H460 tumor xenografts model.
    Hsu YC; Chiang JH; Yu CS; Hsia TC; Wu RS; Lien JC; Lai KC; Yu FS; Chung JG
    Environ Toxicol; 2017 Jan; 32(1):84-98. PubMed ID: 26592500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway.
    Li W; Yu X; Ma X; Xie L; Xia Z; Liu L; Yu X; Wang J; Zhou H; Zhou X; Yang Y; Liu H
    Cell Signal; 2018 Oct; 50():131-141. PubMed ID: 30018008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deguelin Impairs Cell Adhesion, Migration and Invasion of Human Lung Cancer Cells through the NF-[Formula: see text]B Signaling Pathways.
    Hsiao YT; Fan MJ; Huang AC; Lien JC; Lin JJ; Chen JC; Hsia TC; Wu RS; Chung JG
    Am J Chin Med; 2018; 46(1):209-229. PubMed ID: 29402127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
    Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.